Latest Biotechnology News

Page 1 of 101
The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.
Ada Torres
Ada Torres
19 Nov 2026
An independent interim analysis has confirmed statistically significant iPPS benefits in Paradigm’s rest-of-world knee osteoarthritis cohort, giving the company a possible route to continue development despite the overall trial failing its futility test. Any new trial remains subject to funding, creditor approval and regulatory discussions.
Ada Torres
Ada Torres
19 Nov 2026
Racura Oncology has cleared a key ethics hurdle for its pivotal EMILI trial of RC220 in relapsed or refractory acute myeloid leukaemia. The Phase 2b program is funded from existing cash, but efficacy, regulatory and funding tests still stand between the company and Phase 3.
Ada Torres
Ada Torres
18 Nov 2026
Actinogen Medical’s shares have been suspended while it completes analysis of additional data from its pivotal XanaMIA Alzheimer’s trial. The company expects trading to resume no later than 19 November unless the results announcement comes first.
Ada Torres
Ada Torres
17 Nov 2026
AdAlta has taken ownership of the US FDA Orphan Drug Designation for EW-001, strengthening the commercial case for its mesothelioma CAR-T therapy. The designation follows a constructive pre-IND meeting, but approval and clinical success remain unproven.
Ada Torres
Ada Torres
17 Nov 2026
Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
Ada Torres
16 Nov 2026
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
Ada Torres
16 Nov 2026
Moderna’s chief legal officer will retire in March under an agreement that provides US$1.63 million in fixed severance and up to US$8 million linked to litigation outcomes. The package also preserves her salary, benefits and equity vesting through her departure date.
Ada Torres
Ada Torres
14 Nov 2026
Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.
Ada Torres
Ada Torres
13 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
Miro Sciences says Australia’s medicines regulator has completed its inspection of the manufacturing site for StemSmart, supporting the company’s planned Phase 2 Crohn’s disease trial. The inspection is a significant readiness step, but it is not itself approval to begin the study or confirmation of a successful audit outcome.
Ada Torres
Ada Torres
12 Nov 2026
AdAlta has received a larger-than-expected A$1.396 million R&D Tax Incentive refund tied to overseas work on its EW-001 CAR-T therapy. The non-dilutive cash arrives before Australian manufacturing and expected FDA pre-IND meeting minutes in December.
Ada Torres
Ada Torres
12 Nov 2026

Browse the archive

Full archive